[Efficacy of vigabatrin associated with carbamazepine in the treatment of epilepsy. Follow up 1993-1996].
OBJECTIVE
To verify tolerance and clinical efficacy of vigabatrin (VGB), a new antiepileptic drug, in an add-on therapy with carbamazepine (CBZ).


METHODS
From september 1993 to december 1996, 35 patients with partial complex seizures (CPC) and CPC plus secondary generalization were treated, with VGB plus CBZ, VGB dose was 1.41 +/- 0.26 (g/die +/- SD) and CBZ 2.28 +/- 0.60 (g/die +/- SD).


RESULTS
Patients were followed-up every 4 months showing an improvement between 61.5% and 68.8% from baseline.


CONCLUSIONS
In all patients we observed an improvement during the follow-up period. Side effects were mild and well tolerated.
De Romanis
F
F
Dipartimento di Scienze Neurologiche, Università degli Studi La Sapienza, Roma, Italia.
Sopranzi
N
N
D000328:Adult; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use*; D002220:Carbamazepine / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D000927:Anticonvulsants; D002220:Carbamazepine; D005680:gamma-Aminobutyric Acid; D020888:Vigabatrin
Efficacia del vigabatrin in associazione a carbamazepina nel trattamento dell'epilessia. Follow-up 1993-1996.